Birchview Capital’s Axsome Therapeutics AXSM Stock Holding History

Birchview Capital’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.01M	Sell	6,000 -61	-1%	-$10.5K	0.58%	41
2025 Q4	$1.11M	Buy	6,061 +61	+1%	+$8.52K	0.65%	37
2025 Q3	$729K	Hold	6,000	–	–	0.55%	43
2025 Q2	$626K	Hold	6,000	–	–	0.62%	36
2025 Q1	$700K	Buy	6,000 +2,000	+50%	+$228K	0.61%	27
2024 Q4	$338K	Hold	4,000	–	–	0.28%	46
2024 Q3	$359K	Hold	4,000	–	–	0.31%	40
2024 Q2	$322K	Hold	4,000	–	–	0.3%	42
2024 Q1	$319K	Buy	+4,000	New	+$336K	0.26%	46

Other funds holding AXSM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Birchview Capital's AXSM Position: Q1 2026 in Review

Birchview Capital reduced its Axsome Therapeutics (AXSM) stake by 1% in Q1 2026, selling an estimated $10.5K and leaving 6,000 shares worth $1.01M. The position accounts for 0.58% of the portfolio, ranked #41.

Birchview Capital first reported a position in AXSM in Q1 2024 and has held it in 9 quarters since. The position peaked at $1.11M in Q4 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

Birchview Capital held 6,000 shares of Axsome Therapeutics worth $1.01M as of Q1 2026.
Birchview Capital sold 61 Axsome Therapeutics shares in Q1 2026, an estimated $10.5K.
Axsome Therapeutics made up 0.58% of Birchview Capital's portfolio in Q1 2026, its #41 holding.
Birchview Capital first reported a position in Axsome Therapeutics in Q1 2024 and has held it in 9 quarters since.
Birchview Capital's Axsome Therapeutics position peaked at $1.11M in Q4 2025.
409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Birchview Capital's 13F filing for Q1 2026, filed 15 May 2026.